Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Jinjun Ye"'
Autor:
Dashan Ai, Shengnan Hao, Wenbin Shen, Qibing Wu, Shengjian Zhang, Yun Chen, Qi Liu, Jiaying Deng, Hongcheng Zhu, Ke Chen, Miao Mo, Dayong Gu, Yatian Liu, Zhi Zhang, Guoren Zhou, Jingwen Hu, Zhen Zhang, Jinjun Ye, Kuaile Zhao
Publikováno v:
EClinicalMedicine, Vol 69, Iss , Pp 102471- (2024)
Summary: Background: Concurrent chemoradiotherapy is the standard nonoperative treatment for locally advanced esophageal squamous cell carcinoma. However, local recurrence is still the main failure pattern, accounting for more than half of all treatm
Externí odkaz:
https://doaj.org/article/5908ffa8c3f64fe09766164884f2c027
Autor:
Yufan Chang, Xiaochen Zhang, Ge Song, Jing Liu, Chen Lin, Jinjun Ye, Jie Hu, Lei Tang, Zhengtao Ai
Publikováno v:
Energy and Built Environment, Vol 4, Iss 5, Pp 493-505 (2023)
This study aims to evaluate airborne transmission risk in university towns during the COVID-19 pandemic based on surveys of indoor environmental quality (IEQ). Both on-site measurements and questionnaire surveys were carried out in public buildings i
Externí odkaz:
https://doaj.org/article/030ad62beb54408d90422fb0f59df71a
Autor:
Ying Liu, Lei Xiong, Yue Chen, Ruoxue Cai, Xinyu Xu, Tian Wang, Yiyu Guo, Luxi Ruan, Ying Fang, Quanan Zhang, Bo Shen, Jinjun Ye, Guoren Zhou
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 3 (2023)
ABSTRACTThis study aimed to investigate the relationship between complete pathological remission (PCR), tertiary lymphoid structure (TLS) maturation and expression and clinical outcomes of patients with resectable non-small cell lung cancer (NSCLC) r
Externí odkaz:
https://doaj.org/article/5b2c8f3154bd46d196e22dc4e1642aa8
Publikováno v:
Chinese Journal of Lung Cancer, Vol 26, Iss 8, Pp 615-620 (2023)
Lung cancer is the leading cause of cancer death, and non-small cell lung cancer (NSCLC) accounts for 85%. Immunotherapy has significantly improved the clinical prognosis of patients with NSCLC. However, because of the complexity and heterogeneousnes
Externí odkaz:
https://doaj.org/article/a824816b35e9457799f48b83749b85c0
Autor:
Jingyuan Xie, Mo Chen, Hedong Han, Ke Xu, Guihuan Qiu, Xinqing Lin, Yong Song, Jinjun Ye, Tangfeng Lv, Ping Zhan
Publikováno v:
Thoracic Cancer, Vol 14, Iss 15, Pp 1327-1338 (2023)
Abstract Objectives Our research aimed to evaluate the effectiveness of first‐line immune checkpoint inhibitors (ICIs) with etoposide and platinum (EP) for extensive‐stage small cell lung cancer (ES‐SCLC) and identify prognostic factors, as rea
Externí odkaz:
https://doaj.org/article/3d4735eda4554e069c8c2f261ae127c2
Autor:
Hongcheng Zhu, Qiufang Liu, Hao Xu, Miao Mo, Zezhou Wang, Kui Lu, Jialiang Zhou, Junqiang Chen, Xiangpeng Zheng, Jinjun Ye, Xiaolin Ge, Honglei Luo, Qi Liu, Jiaying Deng, Dashan Ai, Shengnan Hao, Junhua Zhang, I Hsuan Tseng, Shaoli Song, Yun Chen, Kuaile Zhao
Publikováno v:
Radiation Oncology, Vol 17, Iss 1, Pp 1-12 (2022)
Abstract Introduction Definitive chemoradiotherapy has established the standard non-surgical treatment for locally advanced esophageal cancer. The standard dose of 50–50.4 Gy has been established decades ago and been confirmed in modern trials. The
Externí odkaz:
https://doaj.org/article/23f6c62c9f474fd0a33ad9853ec260bb
Publikováno v:
Radiation Oncology, Vol 17, Iss 1, Pp 1-9 (2022)
Abstract Purpose This trial aims to explore the efficacy and safety of involved-field irradiation (IFI) combined with paclitaxel plus cisplatin as concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma (ESCC), under the
Externí odkaz:
https://doaj.org/article/cd24921568ce4f99b8e820b184638417
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) represented by gefitinib and erlotinib are widely used in treating non-small cell lung cancer (NSCLC). However, acquired resistance to EGFR-TKI treatment remains a clinical cha
Externí odkaz:
https://doaj.org/article/8c123aa3520c4a9891ba7942034740cc
Autor:
Zhi Zhang, Jinjun Ye, Hui Li, Dayong Gu, Mingyu Du, Dashan Ai, Wei Chen, Ying Fang, Xinyu Xu, Chenguang Bai, Kuaile Zhao, Guoren Zhou
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundImmunotherapy (Programmed cell death 1 blockade) has entered the ranks of advanced esophageal cancer first-line treatment; however, little is known about the efficacy of PD-1 inhibitor as neoadjuvant therapy in resectable esophageal squamou
Externí odkaz:
https://doaj.org/article/ce181094de7640b6aa7924f9b6aeba0f
Publikováno v:
FEBS Open Bio, Vol 11, Iss 7, Pp 1854-1866 (2021)
Dickkopf‐1 (Dkk1) is an inhibitor of Wnt signaling involved in cancer cell proliferation, apoptosis, and migration and angiogenesis. It was previously reported that B cell‐specific Moloney mouse leukemia virus integration site 1 (Bmi1) activates
Externí odkaz:
https://doaj.org/article/0860a1226bbc4b8c849665bb6e63a948